Simmunome provides a no-code platform that utilizes AI-driven simulations and mechanistic modeling to predict drug efficacy and safety profiles before clinical trials. This technology enables pharmaceutical companies to reduce late-stage failures and optimize their drug development pipelines, ultimately saving significant R&D costs.
Funding
$1.5M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
ACBCNA+2Founders
Product
Problem
Pharmaceutical companies face high costs and failure rates in late-stage clinical trials due to the difficulty of accurately predicting drug efficacy and safety profiles early in the development pipeline. Traditional methods often fail to capture the complex biological interactions that determine a drug's success or failure.
Solution
Simmunome offers a no-code, AI-powered SaaS platform that simulates disease biology to predict drug efficacy and safety before clinical trials. By combining mechanistic modeling and machine learning algorithms, the platform provides insights into molecular interactions and potential patient responses. This hybrid approach allows pharmaceutical companies to prioritize drug targets, identify biomarkers, and stratify patient populations, ultimately de-risking clinical development and accelerating time to market. The platform integrates custom data and offers transparent, traceable results, enabling informed decision-making at every stage of drug development.
Target Audience
The primary target audience includes pharmaceutical companies and clinical researchers seeking to improve drug development success rates, reduce R&D costs, and gain deeper insights into drug efficacy and safety.
Features
- BioTarget™ Scoring Tool: Predicts the probability of target efficacy by simulating disease pathways and calculating molecular efficacy scores.
- Omic Signatures™: Identifies biomarkers indicative of disease progression, drug efficacy, and resistance.
- Data Exploration Tool: Provides an intuitive interface for data pre-processing, analysis, and visualization.
- AI Models: Augment biological knowledge and enhance algorithm capabilities.
- Custom Data Integration: Safely leverages client-specific data for targeted results.
- Hybrid Approach: Combines mechanistic modeling and machine learning for reliable predictions.
- Transparent Results: Enables clients to trace results to every interaction influencing efficacy or safety profiles.
- Disease Agnostic: Develops disease models across various therapeutic areas for broad applicability.